Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03004976 : Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke
PhasePhase 2
AgesMin: 18 Years Max: 90 Years
Inclusion Criteria:

1. 18-90 years old

2. Recent, acute, cortical, hemispheric, ischemic stroke in the MCA distribution without
a clinically significant midline shift as detected by MRI as a DWI abnormality

3. NIHSS 6-15 (R) and 6-18 (L) at the time of enrollment with no more than 4 point
increase (worsening of score) from baseline score to 24 hours prior to infusion

4. Subjects must have a platelet count >100,000/µL, hemoglobin >8mg/dL, absolute
lymphocyte count (ALC) ? 1500, and WBC >2,500/µL

5. Subjects who received tPA or underwent endovascular reperfusion may be included in
the study

6. Able to provide consent to study or consent is obtained from the patient's legal

7. Subjects of childbearing potential must practice effective contraception during the
study, and be willing to continue contraception for at least 6 months after
intervention so that, in the opinion of the Investigator, they will not become
pregnant during the course of the study

8. Is a good candidate for the trial, in the opinion of the Investigator

9. Agrees to participate in follow-up visits

10. ABO/Rh and race matched CBU(s) with a minimum of 0.5 x 10^7 TNCC/kg based on the
pre-cryopreservation TNCC is available for infusion

11. Has not had a disease or therapy that would compromise current immune function.

Exclusion Criteria:

An individual is ineligible to participate if any of the following apply:

Exclusionary Medical Conditions:

1. Medical history of neurological or orthopedic pathology with a deficit as a
consequence that results in a modified Rankin Scale >1 before stroke or has a pre
existing cognitive deficit

2. Clinically significant and/or symptomatic hemorrhage associated with stroke

3. Evidence of significant midline shift as assessed by CT or MRI who are felt to be at
high risk for neurological decompensation or need for decompressive hemicraniectomy
due to hemispheric edema

4. New intracranial hemorrhage, edema, or mass effect that may place patient at
increased risk for secondary deterioration when assessed prior to infusion

5. Hypotension as defined as the need for IV pressor support of SBP <90

6. Isolated brain stem stroke

7. Pure lacunar stroke

8. Requires mechanical ventilation. An exception may be patients who were electively
intubated for endovascular reperfusion and then extubated immediately following the

9. Requires a craniotomy

10. Serious psychiatric or neurological disease which could alter evaluation on
functional or cognitive scales

11. Active systemic infection that is felt, at the discretion of the Investigator, to
place the patient at increased risk for participation in this study

12. Documentation of human immunodeficiency virus positive (HIV+) status in the medical

13. Active malignancy within 3 years prior to the start of screening excluding skin
cancers other than melanoma

14. Known hypercoagulable state or coagulopathy deficiencies such as Factor V Leiden,
Antiphospholipid Syndrome (APC), Protein C, Protein S, anticardiolipin antibody,
phospholipid syndrome or Sickle Cell Disease

15. History of or currently active autoimmune disease, or current immunomodulatory
therapy or a recipient of immunomodulatory therapy in the past year.

16. Concurrent illness or condition that in the opinion of the Investigator might
interfere with treatment or evaluation of safety

17. Current or recent history of alcohol or drug abuse, or stroke associated with drug
abuse that Investigator feels may impair therapy or assessments

18. Pregnant as documented by blood test

Prohibited Concomitant or Prior Therapies

1. Patients currently receiving immunosuppressant drugs, not including glucocorticoid
taper, topical/inhaled glucocorticoids

2. History of prior transfusion reaction

3. Currently on dialysis

4. Recipient of bone marrow or organ transplant

5. Renal insufficiency with serum creatinine > 2.0 mg/dL

6. Hepatic insufficiency (bilirubin >2.5mg/dL or transaminases >5x the ULN) Patients
with Gilberts syndrome are eligible for study enrollment if other liver function
tests are normal, regardless of bilirubin level

7. Previous or current treatment with angiogenic growth factors, cytokines, gene or stem
cell therapy

8. Participating in another interventional clinical trial of an investigational therapy
within 30 days of screening

Other Exclusion Criteria

1. Pregnant or lactating women

2. Unable or unwilling to be evaluated for follow-up visits
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557